|
1.
|
|
|
2.
|
|
16 p, 1.8 MB |
Photoactivable Ruthenium-Based Coordination Polymer Nanoparticles for Light-Induced Chemotherapy
/
Zhang, Junda (Institut Català de Nanociència i Nanotecnologia) ;
Ramu, Vadde (Universiteit Leiden. Leiden Institute of Chemistry) ;
Zhou, Xue-Quan (Universiteit Leiden. Leiden Institute of Chemistry) ;
Frias, Carolina (Institut Català de Nanociència i Nanotecnologia) ;
Ruiz-Molina, Daniel (Institut Català de Nanociència i Nanotecnologia) ;
Bonnet, Sylvestre (Universiteit Leiden. Leiden Institute of Chemistry) ;
Roscini, Claudio (Institut Català de Nanociència i Nanotecnologia) ;
Novio Vázquez, Fernando (Institut Català de Nanociència i Nanotecnologia)
Green light photoactive Ru-based coordination polymer nanoparticles (CPNs), with chemical formula [[Ru(biqbpy)](bis)](PF) (biqbpy = 6,6'-bis[N-(isoquinolyl)-1-amino]-2,2'-bipyridine; bis = bis(imidazol-1-yl)-hexane), were obtained through polymerization of the trans-[Ru(biqbpy)(dmso)Cl]Cl complex (Complex 1) and bis bridging ligands. [...]
2021 -  10.3390/nano11113089
Nanomaterials, Vol. 11, Issue 11 (November 2021) , art. 3089
|
|
|
3.
|
|
15 p, 664.9 KB |
Ibrutinib plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia : Primary Analysis Results from the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
/
Wierda, W. G. (University of Texas.) ;
Allan, J. N. (Weill Cornell Medicine) ;
Siddiqi, T. (City of Hope National Medical Center) ;
Kipps, T. J. (UCSD. Moores Cancer Center) ;
Opat, S. (Monash University) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Badoux, X. C. (Ministry of Health) ;
Kuss, B. J. (Flinders University. Medical Centre) ;
Jackson, S. (Middlemore Hospital) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Jacobs, R. M. D. (Levine Cancer Institute) ;
Pagel, J. M. (Swedish Cancer Institute. Center for Blood Disorders and Stem Cell Transplantation) ;
Flinn, I. (Sarah Cannon Research Institute. Tennessee Oncology) ;
Pak, Y. (Pharmacyclics LLC. AbbVie Company) ;
Zhou, C. (Pharmacyclics LLC. AbbVie Company) ;
Szafer-Glusman, E. (Pharmacyclics LLC. AbbVie Company) ;
Ninomoto, J. (Pharmacyclics LLC. AbbVie Company) ;
Dean, James P (Pharmacyclics LLC. AbbVie Company) ;
James, D. F. (Pharmacyclics LLC. AbbVie Company) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. IRCCS Ospedale San Raffaele) ;
Tam, C. S. (Peter MacCallum Cancer Center. St Vincent's Hospital. University of Melbourne) ;
Universitat Autònoma de Barcelona
PURPOSE CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). [...]
2021 - 10.1200/JCO.21.00807
Journal of Clinical Oncology, Vol. 39 Núm. 34 (january 2021) , p. 3853-3865
|
|
|
4.
|
|
41 p, 1.2 MB |
Therapeutic potential of emerging NAD+-increasing strategies for cardiovascular diseases
/
Rotllan, Noemi (Institut d'Investigació Biomèdica Sant Pau) ;
Camacho, Mercedes (Institut d'Investigació Biomèdica Sant Pau) ;
Tondo, Mireia (Institut d'Investigació Biomèdica Sant Pau) ;
Diarte-Añazco, E. M. G. (Institut d'Investigació Biomèdica Sant Pau) ;
Canyelles, Marina (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Méndez Lara, Karen Alejandra (Institut d'Investigació Biomèdica Sant Pau) ;
Benitez, S. (Institut d'Investigació Biomèdica Sant Pau) ;
Alonso Pedrol, Núria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Mauricio Puente, Dídac (Institut d'Investigació Biomèdica Sant Pau) ;
Escola-Gil, Joan Carles (Institut d'Investigació Biomèdica Sant Pau) ;
Blanco Vaca, Francisco (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Julve i Gil, Josep (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular)
Cardiovascular diseases are the leading cause of death worldwide. Aging and/or metabolic stress directly impact the cardiovascular system. Over the last few years, the contributions of altered nicotinamide adenine dinucleotide (NAD+) metabolism to aging and other pathological conditions closely related to cardiovascular diseases have been intensively investigated. [...]
2021 - 10.3390/antiox10121939
Antioxidants, Vol. 10 Núm. 12 (december 2021) , p. 1939
|
|
|
5.
|
|
28 p, 10.5 MB |
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model
/
Alé, Albert (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Bruna, Jordi (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Morell, Marta (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
van de Velde, Helgi (Janssen Research and Development) ;
Monbaliu, Johan (Janssen Research and Development) ;
Navarro, X. (Xavier) (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Udina i Bonet, Esther (Universitat Autònoma de Barcelona. Institut de Neurociències)
Bortezomib (BTZ), a proteasome inhibitor, is an effective anti-neoplastic drug used in the treatment of multiple myeloma and mantle cell lymphoma. However, it can induce a reversible peripheral neuropathy that may lead to treatment discontinuation. [...]
2014 - 10.1016/j.expneurol.2013.12.020
Experimental Neurology, Vol. 253 (march 2014) , p. 165-173
|
|
|
6.
|
|
12 p, 1.2 MB |
Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy
/
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Sánchez Martínez, M. Olga (Vall d'Hebron Institut d'Oncologia) ;
Martínez, Sandra (Vall d'Hebron Institut d'Oncologia) ;
Domínguez, Carmen (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Dienstmann, Rodrigo (Vall d'Hebron Institut d'Oncologia) ;
Ruíz-Pace, Fiorella (Vall d'Hebron Institut d'Oncologia) ;
Céspedes, Maria Concepció (Hematologic Molecular Genetics Unit. Hematology Department. Hospital Universitari Vall d'Hebron. ERN-EuroBloodNet Member) ;
Peñuelas, Ángeles (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Llurba, E. (Institut d'Investigació Biomèdica Sant Pau) ;
Córdoba, Octavi (Institut d’Investigació Sanitària Illes Balears) ;
Universitat Autònoma de Barcelona
Anthracyclines and taxanes are being used as a standard treatment for breast cancer diagnosed during pregnancy. These chemotherapy regimens allow the continuation of pregnancy without delaying cancer treatment with relatively good maternal and neonatal outcomes. [...]
2021 - 10.3390/cancers13040923
Cancers, Vol. 13 (february 2021)
|
|
|
7.
|
|
15 p, 2.1 MB |
Tetraploidy-associated genetic heterogeneity confers chemo-radiotherapy resistance to colorectal cancer cells
/
Galofré, Claudia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Gönül Geyik, Öykü (Dokuz Eylul University. Department of Medical Biology) ;
Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Wangsa, Darawalee (National Institute of Health (Bethesda, EUA)) ;
Hirsch, Daniela (National Institute of Health (Bethesda, EUA)) ;
Parra, Carolina (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Saez, Jordi (Hospital Clínic i Provincial de Barcelona) ;
Mollà, Meritxell (Hospital Clínic i Provincial de Barcelona) ;
Yüce, Zeynep (Dokuz Eylul University. Department of Medical Biology) ;
Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Ried, Thomas (National Institute of Health (Bethesda, EUA)) ;
Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
Tetraploidy, or whole-genome duplication, is a common phenomenon in cancer and preludes chromosome instability, which strongly correlates with disease progression, metastasis, and treatment failure. Therefore, it is reasonable to hypothesize that tetraploidization confers multidrug resistance. [...]
2020 - 10.3390/cancers12051118
Cancers, Vol. 12, issue 5 (May 2020) , art. 1118
|
|
|
8.
|
|
11 p, 2.5 MB |
Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy : Systematic Review and Meta-Analysis
/
Krajewski, Wojciech (Wrocław Medical University, Wroclaw, Poland) ;
Nowak, Łukasz (Wrocław Medical University, Wroclaw, Poland) ;
Moschini, Marco (Luzerner Kantonsspital, Lucerne, Switzerland) ;
Poletajew, Sławomir (Centre of Postgraduate Medical Education, Warsaw, Poland) ;
Chorbińska, Joanna (Wrocław Medical University, Wroclaw, Poland) ;
Necchi, Andrea (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) ;
Montorsi, Francesco (IRCCS Ospedale San Raffaele, Milan, Italy) ;
Briganti, Alberto (IRCCS Ospedale San Raffaele, Milan, Italy) ;
Sanchez-Salas, Rafael (Université Paris-Descartes, Paris, France) ;
Shariat, Shahrokh F. (Charles University, Prague, Czech Republic) ;
Palou, Juan ;
Babjuk, Marek (Institut d'Investigació Biomèdica Sant Pau) ;
Teoh, Jeremy Y. C. (The Chinese University of Hong Kong, Hong Kong) ;
Soria, Francesco (San Giovanni Battista Hospital) ;
Pradere, Benjamin (University Hospital of Tours, Tours) ;
Ornaghi, Paola Irene (Luzerner Kantonsspital, Lucerne, Switzerland) ;
Pawlak, Aleksandra (Wroclaw University of Environmental and Life Sciences, Wrocław, Poland) ;
Dembowski, Janusz (Wrocław Medical University, Wroclaw, Poland) ;
Zdrojowy, Romuald (Wrocław Medical University, Wroclaw, Poland) ;
Universitat Autònoma de Barcelona
Background: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) with pelvic lymph-node dissection is the standard treatment for cT2-4a cN0 cM0 muscle-invasive bladder cancer (MIBC). [...]
2021 - 10.3390/jcm10040651
Journal of clinical medicine, Vol. 10 (february 2021)
|
|
|
9.
|
|
19 p, 2.8 MB |
The Beneficial Effects of Heme Oxygenase 1 and Hydrogen Sulfide Activation in the Management of Neuropathic Pain, Anxiety- and Depressive-like Effects of Paclitaxel in Mice
/
Roch, Gerard (Institut d'Investigació Biomèdica Sant Pau) ;
Batallé Melgarejo, Gerard (Institut d'Investigació Biomèdica Sant Pau) ;
Bai, Xue (Institut d'Investigació Biomèdica Sant Pau) ;
Pouso-Vázquez, Enric (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Rodríguez, Laura (Universitat Autònoma de Barcelona. Institut de Neurociències) ;
Pol, Olga (Universitat Autònoma de Barcelona. Institut de Neurociències)
Chemotherapy-induced peripheral neuropathy constitutes an unresolved clinical problem that severely decreases the quality of the patient's life. It is characterized by somatosensory alterations, including chronic pain, and a high risk of suffering mental disorders such as depression and anxiety. [...]
2022 - 10.3390/antiox11010122
Antioxidants, Vol. 11 (january 2022)
|
|
|
10.
|
|
11 p, 726.2 KB |
Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061
/
Van Cutsem, Eric (University Hospitals Gasthuisberg (Leuven, Bélgica)) ;
Amonkar, Mayur (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Fuchs, Charles S. (Yale School of Medicine. Yale Cancer Center) ;
Alsina, Maria (Vall d'Hebron Institut d'Oncologia) ;
Özgüroğlu, Mustafa (Istanbul University-Cerrahpaşa. Department of Internal Medicine, Medical Oncology, and Clinical Trial Unit) ;
Bang, Yung-Jue (Seoul National University College of Medicine. Department of Internal Medicine) ;
Chung, Hyun Cheol (Yonsei University College of Medicine. Department of Medical Oncology) ;
Muro, Kei (Aichi Cancer Center Hospital) ;
Goekkurt, Eray (University Cancer Center Hamburg. North-German Trial Center for Innovative Oncology) ;
Benson, Al B. (Northwestern University. Robert H. Lurie Comprehensive Cancer Center) ;
Sun, Weijing (University of Kansas. Department of Internal Medicine and Medical Oncology) ;
Wainberg, Zev A. (David Geffen School of Medicine at UCLA. Department of Medicine and Hematology and Oncology) ;
Norquist, Josephine M. (Merck & Co., Inc.. Center for Observational and Real World Evidence) ;
Chen, Xinqun (Merck & Co., Inc.. Department of Medical Oncology) ;
Shih, Chie-Schin (Merck & Co., Inc.. Department of Medical Oncology) ;
Shitara, Kohei (National Cancer Center Hospital. Department of Gastrointestinal Oncology) ;
Universitat Autònoma de Barcelona
In the primary analysis population (i. e. , PD-L1 combined positive score [CPS] ≥ 1) of the phase 3 KEYNOTE-061 study (NCT02370498), pembrolizumab did not significantly prolong overall survival or progression-free survival. [...]
2021 - 10.1007/s10120-021-01200-w
Gastric Cancer, Vol. 24 (august 2021) , p. 1330-1340
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
